This database contains 542 studies, archived under the term: "middle aged"
Click here to filter this large number of results.
Improved end-of-life care for patients with dementia: greater family satisfaction and possibly greater end-of-life comfort
van der Steen, Jenny T.,
van Soest-Poortvliet, Mirjam C.,
Gijsberts, Marie-José H. E.,
Onwuteaka-Philipsen, Bregje D.,
Achterberg, Wilco P.,
Ribbe, Miel W.,
Deliens, Luc,
de Vet, Henrica C. W.
Objective: To analyse possible trends in families’ evaluations of the quality of end-of-life care and the quality of dying in dementia.; Design: Analysis of individual patient data from 3 studies (2 solely retrospective (after death) and 1 partly prospective).; Method: We combined data on 372 residents with dementia from 38 nursing homes and 13 residential […]
The implementation of integrated emotion-oriented care: did it actually change the attitude, skills and time spent of trained caregivers?
van der Kooij, C.,
Droes, R.,
de Lange, J.,
Ettema, T.,
Cools, H.,
van Tilburg, W.
Background: Successful implementation is a vital precondition for investigating the outcome of care innovation. This study concerned the evaluation of the implementation of integrated emotion-oriented care (IEOC) in psychogeriatric nursing home wards. The main question was whether the trained caregivers actually applied the knowledge and techniques of IEOC during their daily work.; Methods: The study […]
Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up
van den Bogaard, S. J. A.,
Dumas, E. M.,
Hart, E. P.,
Milles, J.,
Reilmann, R.,
Stout, J. C.,
Craufurd, D.,
Gibbard, C. R.,
Tabrizi, S. J.,
van Buchem, M. A.,
van der Grond, J.,
Roos, R. A. C.
Background and Purpose: MTI is a quantitative MR imaging technique that has recently demonstrated structural integrity differences between controls and patients with HD. Potentially, MTI can be used as a biomarker for monitoring disease progression. To establish the value of MTI as a biomarker, we aimed to examine the change in these measures during the […]
Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
Unterberger, Ursula,
Lachmann, Ingolf,
Voigtländer, Till,
Pirker, Walter,
Berghoff, Anna S.,
Flach, Katharina,
Wagner, Uta,
Geneste, Aline,
Perret-Liaudet, Armand,
Kovacs, Gabor G.
With the aim to evaluate the significance and reliability of detecting disease-specific α-synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We used a commercial antibody (5G4) that does not bind to the physiological monomeric form of α-synuclein, but is highly specific for the disease-associated forms, including high molecular weight fraction of […]
Study of the voxel-based specific regional analysis system for Alzheimer’s disease imaging sequence after magnetic resonance apparatus replacement
Tsukagoshi, Yuki,
Kanai, Yoshihiro,
Yasui, Gou,
Abe, Yuuji,
Maemura, Keisuke,
Nakazawa, Masaki,
Yamaji, Yuugo,
Mihara, Ban
In our institute, an MR apparatus, MAGNETOM VISION (Siemens) was replaced by ECHELON Vega (HITACHI). Z-score data acquired by MPRAGE (VISION) was compared with those by radio frequency-spoiled steady-state acquisition with rewinded gradient echo (RSSG) and gradient echo inversion recovery (GEIR) (ECHELON). For this study, ten normal volunteers were recruited and their data ware obtained […]
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease
Trzepacz, Paula T.,
Cummings, Jeffrey,
Konechnik, Thomas,
Forrester, Tammy D.,
Chang, Curtis,
Dennehy, Ellen B.,
Willis, Brian A.,
Shuler, Catherine,
Tabas, Linda B.,
Lyketsos, Constantine
Background: Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer’s disease (AD).; Methods: Outpatients (n = 132) with probable AD and A/A randomized to 12 weeks of double-blind treatment with 3-mg po mibampator or placebo were assessed using the 4-domain A/A subscale of the Neuropsychiatric Inventory […]
A randomized controlled pilot study to evaluate a technology platform for the assisted living of people with dementia and their carers
Torkamani, Mariam,
McDonald, Louise,
Saez Aguayo, Ignasi,
Kanios, Christos,
Katsanou, Maria-Nefeli,
Madeley, Laura,
Limousin, Patricia D.,
Lees, Andrew J.,
Haritou, Maria,
Jahanshahi, Marjan
The use of telemedicine is becoming increasingly popular in assisting with the home management of People with Dementia (PwD) by offering services to the carers that may enhance their ability to care for their relative for longer. A computerized platform, ALADDIN, was evaluated in its usefulness to reduce carer burden and distress and to improve […]